Harmony Biosciences
Harmony Biosciences is dedicated to developing innovative treatments for rare neurological diseases, with a focus on sleep/wake disorders, neurobehavioral conditions, and rare epilepsy. Guided by principles of empathy and innovation, the company aims to improve patient outcomes through patient-focused drug development, community support, and advancing scientific research.
Industries
Nr. of Employees
large (251-1000)
Harmony Biosciences
630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA 19462
Products
Pitolisant tablets (histamine H3 receptor antagonist/inverse agonist)
An orally administered H3 receptor antagonist/inverse agonist indicated for sleep/wake disorders; developed under license and approved for commercial use in specified regulatory jurisdictions.
Pharmaceutically produced cannabidiol transdermal gel (ZYN002)
A pharmaceutically manufactured cannabidiol formulated as a transdermal gel (no THC) developed for behavioral symptoms in neurobehavioral disorders; in late‑stage clinical development for Fragile X syndrome.
Clemizole hydrochloride (EPX-100) — 5-HT receptor modulator
A centrally active compound that modulates serotonin receptor subtypes being developed as adjunctive therapy for rare epilepsy syndromes including Dravet syndrome and Lennox-Gastaut syndrome; has received orphan drug designation.
Lorcaserin liquid formulation (EPX-200)
A liquid oral formulation of a selective 5‑HT2C agonist in IND‑enabling development for developmental and epileptic encephalopathies.
Orexin-2 receptor (OX2R) oral agonist (BP1.15205)
A highly potent and selective oral orexin-2 receptor agonist representing a new chemical series developed for symptoms of narcolepsy and other sleep/wake disorders.
MCHR1 antagonist (HBS-102)
A melanin-concentrating hormone receptor 1 antagonist under development for indications including Prader-Willi syndrome, with mechanisms related to feeding behaviors, REM sleep regulation and mood.
Pitolisant tablets (histamine H3 receptor antagonist/inverse agonist)
An orally administered H3 receptor antagonist/inverse agonist indicated for sleep/wake disorders; developed under license and approved for commercial use in specified regulatory jurisdictions.
Pharmaceutically produced cannabidiol transdermal gel (ZYN002)
A pharmaceutically manufactured cannabidiol formulated as a transdermal gel (no THC) developed for behavioral symptoms in neurobehavioral disorders; in late‑stage clinical development for Fragile X syndrome.
Clemizole hydrochloride (EPX-100) — 5-HT receptor modulator
A centrally active compound that modulates serotonin receptor subtypes being developed as adjunctive therapy for rare epilepsy syndromes including Dravet syndrome and Lennox-Gastaut syndrome; has received orphan drug designation.
Lorcaserin liquid formulation (EPX-200)
A liquid oral formulation of a selective 5‑HT2C agonist in IND‑enabling development for developmental and epileptic encephalopathies.
Orexin-2 receptor (OX2R) oral agonist (BP1.15205)
A highly potent and selective oral orexin-2 receptor agonist representing a new chemical series developed for symptoms of narcolepsy and other sleep/wake disorders.
MCHR1 antagonist (HBS-102)
A melanin-concentrating hormone receptor 1 antagonist under development for indications including Prader-Willi syndrome, with mechanisms related to feeding behaviors, REM sleep regulation and mood.
Services
Portal-based submission, two-phase scientific review and potential funding for investigator-initiated interventional, observational, or survey studies that align with stated scientific interests; investigators retain responsibility for legal and regulatory conduct.
Funding and sponsorship for independent scientific and educational conferences, CME and non-CME programs that contribute to patient care or scientific knowledge within the company's therapeutic areas.
Grant program supporting nonprofit initiatives addressing disparities and access to care in rare neurological disease communities; includes defined application requirements and funding decisions within a review timeline.
Provision of educational materials, advocacy organization resources, and links to active clinical trial websites to support patients, caregivers, and trial recruitment.
Portal-based submission, two-phase scientific review and potential funding for investigator-initiated interventional, observational, or survey studies that align with stated scientific interests; investigators retain responsibility for legal and regulatory conduct.
Funding and sponsorship for independent scientific and educational conferences, CME and non-CME programs that contribute to patient care or scientific knowledge within the company's therapeutic areas.
Grant program supporting nonprofit initiatives addressing disparities and access to care in rare neurological disease communities; includes defined application requirements and funding decisions within a review timeline.
Provision of educational materials, advocacy organization resources, and links to active clinical trial websites to support patients, caregivers, and trial recruitment.
Expertise Areas
- Clinical trial management for rare neurological diseases
- Small-molecule discovery and preclinical development
- Formulation development (oral and transdermal)
- Regulatory affairs and orphan drug development
Key Technologies
- Transdermal drug delivery (pharmaceutical gel)
- Oral small-molecule therapeutics and tablet/lipid/liquid formulations
- Formulation and excipient optimization for PK modulation
- Receptor-targeted pharmacology (H3, OX2R, MCHR1, 5‑HT receptors)